Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study.
B. I. Sikic
Research Funding - Human Genome Sciences
S. G. Eckhardt
Research Funding - Human Genome Sciences
G. Gallant
Employment or Leadership Position - Human Genome Sciences
Stock Ownership - Human Genome Sciences
H. A. Burris
No relevant relationships to disclose
D. R. Camidge
No relevant relationships to disclose
A. D. Colevas
No relevant relationships to disclose
S. F. Jones
No relevant relationships to disclose
W. A. Messersmith
No relevant relationships to disclose
H. A. Wakelee
No relevant relationships to disclose
H. Li
Employment or Leadership Position - Human Genome Sciences
Stock Ownership - Human Genome Sciences
P. G. Kaminker
Employment or Leadership Position - Human Genome Sciences
Stock Ownership - Human Genome Sciences
S. Morris
Employment or Leadership Position - Aegera Therapeutics
J. R. Infante
Consultant or Advisory Role - Novartis